Luis Álvarez-Vallina

Luis Álvarez-Vallina

Luis Álvarez-Vallina
Cargo

Head of the Joint Cancer Immunotherapy Unit H12O/CNIO (Hospital Universitario 12 de Octubre/Centro Nacional de Investigaciones Oncológicas).

Reactions: immunotherapy clinical trial improves prognosis of a type of leukaemia in infants

A phase 2 clinical trial has analysed the safety and efficacy of adding immunotherapy to traditional chemotherapy to treat a subtype of acute lymphoblastic leukaemia in children under one year of age. This subtype of leukaemia, although rare in absolute terms, is the most common in children of this age, and its prognosis in this age group had not improved in recent years. The immunotherapy used, a bispecific antibody that binds to tumour cells on the one hand and T lymphocytes on the other, improved two-year survival from 66% to 93% in treated patients, according to The New England Journal of Medicine (NEJM).

0

Reactions to trial using CAR-T cells prepared from donors to treat multiple myeloma

Approved therapies to treat various tumours using CAR-T cells are based on the modification of the patient's own lymphocytes in the laboratory, which delays their administration. A phase 1 clinical trial has used ready-made donor cells to treat patients with multiple myeloma. The results are published in the journal Nature Medicine.

0

Reactions: two studies add circuitry to CAR-T cells to improve immunotherapy

Two preclinical studies published in the journal Science have introduced new bioengineered modifications to CAR-T cells in an attempt to make them more potent and safer in their anti-tumour action. These variations allow their activity to be enhanced only in the vicinity of the tumour or their actions to be regulated on demand.

0